An Overview of an Immuno-Oncology Panel for Standardized Profiling of Immune Status

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.